Related Experiment Videos
Pathobiology of lipopolysaccharide
1Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock 72205, USA. pmayeux@biomed.uams.edu
Journal of Toxicology and Environmental Health
|August 8, 1997
Summary
Lipopolysaccharide (LPS), a gram-negative bacterial component, causes significant deaths annually. This review examines LPS-induced septicemia, focusing on signal transduction pathways and current therapeutic strategies for better understanding and treatment.
Area of Science:
- Microbiology
- Immunology
- Pathophysiology
Background:
- Lipopolysaccharide (LPS) is a critical component of gram-negative bacterial cell walls.
- LPS triggers severe health consequences, including septicemia, leading to significant mortality in the United States.
- Cellular responses to LPS vary, and released mediators can impact non-target cells, complicating disease progression.
Purpose of the Study:
- To review the current understanding of lipopolysaccharide's role in septicemia development.
- To examine the signal transduction pathways activated by LPS.
- To summarize existing and potential therapeutic approaches for LPS-induced conditions.
Main Methods:
- Literature review of studies on lipopolysaccharide.
- Analysis of signal transduction mechanisms in response to LPS.
- Evaluation of current therapeutic strategies for septicemia.
Main Results:
- Different cell types exhibit distinct responses to lipopolysaccharide.
- LPS induces the release of autacoids and cytokines, affecting cellular functions broadly.
- Current therapies for LPS-related conditions remain largely supportive and often ineffective.
Conclusions:
- Understanding LPS-mediated signal transduction is crucial for developing effective treatments.
- Further research into targeted therapies is needed to combat LPS-induced septicemia and its sequelae.
- Advances in understanding septic shock etiology have not yet translated into significantly improved patient outcomes.